Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 4/20 | 0.42 |
| ▸ | BCAT1 | P54687 | 4/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24824853 | 0.86 | AR (0.62) | ARBCAT2BCAT1 | |
| SCHEMBL23163257 | 0.83 | BCAT2 (0.50) | ARBCAT2BCAT1SLC22A12KDM4E | |
| SCHEMBL24824105 | 0.81 | KDM4E (0.50) | ARBCAT2BCAT1SLC22A12KDM4E | |
| SCHEMBL2566487 | 0.75 | NPC1 (0.60) | ARSLC22A12NPC1KDM4EUSP2 | |
| SCHEMBL24824151 | 0.75 | ALDH1A1 (0.43) | ARBCAT2BCAT1SLC22A12KDM4E | |
| SCHEMBL8777742 | 0.72 | CD44 (0.46) | ARNPC1ALDH1A1TSHR | |
| SCHEMBL4181001 | 0.72 | AR (0.73) | AR | |
| SCHEMBL6177741 | 0.72 | AR (0.51) | ARBCAT2BCAT1SLC22A12TSHR | |
| SCHEMBL24824003 | 0.71 | AR (0.62) | ARBCAT2BCAT1KDM4EUSP2 | |
| SCHEMBL522176 | 0.69 | AR (0.68) | ARSLC22A12ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411381-A1 | PYRIMIDINEDIONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411381-A1 | PYRIMIDINEDIONE DERIVATIVES | DPYD, TYMP, TYMS | AR 2511/4885BCAT2 3754/4885BCAT1 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.